Last reviewed · How we verify
Ultibro®
At a glance
| Generic name | Ultibro® |
|---|---|
| Also known as | Indacaterol 110 µg/Glycopyrronium 50 µg, LABA/LAMA |
| Sponsor | Laval University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product (PHASE1)
- Description of the Ability to Learn How to Handle Inhaler Devices in COPD (PHASE4)
- 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (PHASE3)
- A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence (PHASE3)
- Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs
- Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD (PHASE4)
- DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
- Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ultibro® CI brief — competitive landscape report
- Ultibro® updates RSS · CI watch RSS
- Laval University portfolio CI